机构：[1]Department of Oncology, The Afliated Hospital of Southwest Medical University, Luzhou, Sichuan,China[2]Department of Oncology, Anyue Hospital of Traditional Chinese Medicine, Second Ziyang Hospital ofTraditional Chinese Medicine, Ziyang, Sichuan, China[3]Laboratory of Systems Biology and Bioinformatics,Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran[4]Department of Genetics, Faculty ofAdvanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran[5]Departmentof Biology, Faculty of Science, University of Zanjan, Zanjan, Iran[6]Department of Pharmacology, School ofPharmacy, Southwest Medical University, Luzhou, Sichuan, China[7]Graduate Institute of Biomedical Sciences,Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung,Taiwan[8]Department of Pathology, The Afliated Hospital of Southwest Medical University, Luzhou, Sichuan,China[9]Institute of Materia Medical, College of Pharmacy, Army Medical University (Third Military MedicalUniversity), Chongqing, China
BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy. In order to assess the diagnostic value of phosphatidylserine-specific phospholipase A1-alpha (PLA1A), a potent lysophospholipid mediating the production of lysophosphatidylserine, PLA1A mRNA and serum levels were compared in subjects with malignant melanoma (n = 18), primary melanoma (n = 13), and healthy subjects (n = 10). Additionally, the correlation between histopathological subtypes of BRAF/NRAS-mutated melanoma and PLA1A was analyzed. PLA1A expression was significantly increased during melanogenesis and positively correlated to disease severity and histopathological markers of metastatic melanoma. PLA1A mRNA and serum levels were significantly higher in patients with BRAF-mutated melanoma compared to the patients with NRAS-mutated melanoma. Notably, PLA1A can be used as a diagnostic marker for an efficient discrimination between naïve melanoma samples and advanced melanoma samples (sensitivity 91%, specificity 57%, and AUC 0.99), as well as BRAF-mutated melanoma samples (sensitivity 62%, specificity 61%, and AUC 0.75). Our findings suggest that PLA1A can be considered as a potential diagnostic marker for advanced and BRAF-mutated melanoma.
基金：
Tis work was supported in part by Southwest Medical University Grant and the Research Foundation of the Science and Technology Department of Sichuan Province (No, 18080) and was funded by Saber Imani.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]Department of Oncology, The Afliated Hospital of Southwest Medical University, Luzhou, Sichuan,China[2]Department of Oncology, Anyue Hospital of Traditional Chinese Medicine, Second Ziyang Hospital ofTraditional Chinese Medicine, Ziyang, Sichuan, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yang Gang,Liu Shuya,Maghsoudloo Mazaher,et al.PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.[J].Scientific reports.2021,11(1):6056.doi:10.1038/s41598-021-85595-7.
APA：
Yang Gang,Liu Shuya,Maghsoudloo Mazaher,Shasaltaneh Marzieh Dehghan,Kaboli Parham Jabbarzadeh...&Imani Saber.(2021).PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer..Scientific reports,11,(1)
MLA：
Yang Gang,et al."PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.".Scientific reports 11..1(2021):6056
